| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -122,417 | -85,485 |
| Accretion of discount on held-to-maturity securities | 5,671 | 3,275 |
| Stock-based compensation | 14,039 | 8,198 |
| Depreciation and amortization | 46 | 31 |
| Accrued interest receivable | -15 | -5 |
| Prepaid, other current assets, and other assets | -902 | 2,658 |
| Accounts payable and accrued liabilities | 8,558 | 7,528 |
| Net cash used in operating activities | -104,528 | -75,656 |
| Purchases of marketable securities | 546,264 | 245,757 |
| Maturities of marketable securities | 260,000 | 110,000 |
| Purchases of property and equipment | 0 | 0 |
| Net cash used in investing activities | -286,264 | -135,757 |
| Proceeds from issuance of common stock in public offering, net of offering costs and pursuant to atm agreement, net of issuance costs-Public Offering September2025 | 270,200 | - |
| Proceeds from issuance of common stock in public offering, net of offering costs and pursuant to atm agreement, net of issuance costs-Public Offering | - | 188,880 |
| Proceeds from issuance of common stock in public offering, net of offering costs and pursuant to atm agreement, net of issuance costs-Public Offering March2025 | 188,880 | - |
| Proceeds from issuance of common stock in public offering, net of offering costs and pursuant to atm agreement, net of issuance costs-At The Market | 27,336 | 8,943 |
| Proceeds from stock option exercises | 7,826 | 1,202 |
| Proceeds from issuance of common stock for cash under employee stock purchase plan | 142 | 142 |
| Payment of shelf offering costs | 86 | 57 |
| Proceeds from issuance of common stock and pre-funded warrants in a private placement offering, net of offering costs | 0 | 0 |
| Net cash provided by financing activities | 494,298 | 199,110 |
| Net increase in cash and cash equivalents | 103,506 | -12,303 |
| Cash and cash equivalents at beginning of period | 114,091 | - |
| Cash and cash equivalents at end of period | 217,597 | - |
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)